Achieving the Required Area %RSD for the Losartan Potassium Compendial Method

Significance of the Topic

Achieving precise and repeatable quantitation of pharmaceutical compounds is critical for quality control and regulatory compliance. The United States Pharmacopeia (USP) <621> chapter specifies stringent system suitability criteria for compendial assays, including a requirement for low relative standard deviation (RSD) in peak areas. Implementing robust methods that reliably meet these criteria is essential for laboratories testing losartan potassium, a widely used antihypertensive agent.

Objectives and Study Overview

This study evaluates the performance of the Agilent 1260 Infinity II liquid chromatography system in achieving the USP-mandated area %RSD for the losartan potassium compendial assay. The main objectives are to demonstrate injection precision under the specified chromatographic conditions, assess interday and intraday repeatability, and verify method robustness over multiple injections with a 100% methanol diluent and low injection volumes.

Methodology and Instrumentation

The assay was conducted according to USP compendial guidelines. Key chromatographic parameters included:

• Column: Agilent ZORBAX Eclipse Plus C18, 250 × 4.6 mm, 5 µm
• Mobile Phase: 0.1% orthophosphoric acid in water (40%) and acetonitrile (60%)
• Flow Rate: 1.0 mL/min
• Injection Volume: 10 µL
• Column Temperature: 35 °C
• Detection Wavelength: 254 nm
• Run Time: 10 minutes
• Diluent: Methanol

Instrumentation details:

• Agilent 1260 Infinity II Quaternary Pump
• Agilent 1260 Infinity II Vialsampler with integrated column compartment and sample cooler
• Agilent 1260 Infinity II Diode Array Detector WR
• Software: Agilent OpenLab CDS 2.3.0

Results and Discussion

Interday and intraday precision were assessed over three consecutive days with two trials per day, each comprising six replicate injections. The system achieved area %RSD values well below the USP requirement: trial 1 and trial 2 on day 1 showed area RSDs of 0.14% and 0.06%, respectively, and retention time RSDs below 0.08%. Similar performance was observed on subsequent days. A robustness test with 50 consecutive injections yielded an area RSD of 0.16% and a retention time RSD of 0.14%. These results confirm the 1260 Infinity II LC delivers consistent, precise quantitation for losartan potassium.

Benefits and Practical Applications of the Method

• Exceptional injection precision supports compliance with updated USP system suitability criteria.
• Reliable performance with 100% organic diluents and low sample volumes.
• Enhanced method robustness reduces reanalysis and increases laboratory throughput.
• Applicable to regulated environments requiring stringent quality assurance.

Future Trends and Applications

Advances in pharmaceutical analysis may include integration of real-time data analytics, automated system suitability monitoring, and miniaturized high-throughput platforms. Further developments in column technology and detection systems could improve sensitivity and reduce solvent consumption, while continued monograph modernization will drive more stringent performance benchmarks.

Conclusion

The Agilent 1260 Infinity II LC system demonstrates outstanding precision and robustness for the losartan potassium compendial method, consistently meeting and exceeding USP <621> requirements. Its reliable performance in both low-volume injections and extended sequences of replicates makes it a valuable asset for pharmaceutical quality control laboratories.

References

1. United States Pharmacopeia. USP-NF 40. General Chapter <621> Chromatography.